Most non-Hodgkin lymphomas do not display the same genetic alteration as classical Hodgkin lymphoma, and are much less susceptible to PD-1 blockade.
Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity.
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.
Hodgkin Lymphoma: Assay May Predict Post-transplantation Relapse, Possibly Guiding Non-transplant OptionsOctober 03, 2017
The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to the individual patient.
Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.
Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.
Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.
PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.
Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.
Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.
A diagnosis of Waldenstrom's Macroglobulinemia can leave you and your loved ones feeling uncertain, anxious and overwhelmed.
Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin LymphomaJuly 06, 2016
BeGEV appears to provide clinical benefit for patients with relapsed or refractory Hodgkin lymphoma, and ought to be developed further.
Early MRI-based screening may reduce breast cancer mortality among women treated with radiotherapy (RT) for childhood Hodgkin lymphoma.
Hodgkin lymphoma incidence was lower in areas of the United States with more ultraviolet radiation exposure.
Patients with advanced-stage Hodgkin lymphoma who were at high risk for treatment failure as determined by interim PET response.
Standard ABVD was associated with a significant improvement in survival in older patients with Hodgkin lymphoma.
Significant disparities have been found in HIV-positive black patients with Hodgkin lymphoma, with regard to both rate of diagnosis and chemotherapy usage.
Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Involved-field radiotherapy (IF-RT) should be considered standard of care for stage 1A nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
Recent declines in nodular sclerosis (NS) rates represented true incidence changes in Hodgkin lymphoma (HL).
For Hodgkin's lymphoma, brentuximab vedotin is associated with improved progression-free survival after autologous stem-cell transplant.
PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.
Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the standard of care for early-stage favorable Hodgkin's lymphoma
Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted in better survival.
Nivolumab-mediated programmed cell death-1 (PD-1) blockade produced responses in classical Hodgkin lymphoma (cHL).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy